Stay informed with the latest updates for the inheritable blood disorders community.

Industry
Study Shows Positive Joint Outcomes in Hemophilia A Patients Treating Prophylactically with ELOCTATE®
Study Shows Positive Joint Outcomes in…
Industry
ICER Review of Emicizumab for People with Hemophilia A and Inhibitors
FDA Accepts Application for Bayer’s Investigational Hemophilia A Therapy
Industry
FDA Grants Breakthrough Therapy Designation for BioMarin’s Investigative Hemophilia A Gene Therapy
FDA Grants Breakthrough Therapy Designation for…
Medical
New Medscape Activity Describes Latest Advances in Inhibitor Management
Partners Clinical Management Module Focuses on ITI and Inhibitors
Industry
Shire’s Hemophilia Gene Therapy Granted Orphan Drug Status by FDA
Shire’s Hemophilia Gene Therapy Granted Orphan Drug Status by FDA
Advocacy & Legislative
Joint Endorsement of Alexander-Murray
Joint Endorsement of Alexander-Murray
Industry
uniQure Announces First Hemophilia B Patient Treated in Phase III Gene Therapy Trial
UniQure’s Investigational Hemophilia B Gene Therapy to Move Forward in…
Medical
New Study Demonstrates Potential for Reducing Factor VIII Inhibitors in Hemophilia A
New Study Demonstrates Potential for Reducing Factor VIII…
Advocacy & Legislative
NHF Healthcare Update: Trump Executive Order and Cost-Sharing Reductions Changes
NHF Healthcare Update: Trump Executive Order and Cost-Sharing…
NBDF & Community
NHF Announces Kevin Child Scholarship Winner for 2017
NHF Announces Kevin Child Scholarship Winner for 2017
Honoring George McCoy
Honoring George McCoy
Medical
2017 Mid-Year Hemophilia Update Now Available from Medscape
2017 Mid-Year Hemophilia Update Now Available from Medscape
Help for Puerto Rico
Help for Puerto Rico
Industry
Catalyst’s Trial Update Includes Reports of Antibody Responses
Catalyst Reports Positive Results in First…
NHF Research Recognized by US Specialty Pharmacists
NHF Research Recognized by US Specialty Pharmacists